THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS’ PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS: Research Article: Mood Disorders Prescribing Survey
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Optimal successive treatment decisions are not well established after an initial medication nonresponse in major depressive disorder or bipolar disorder. While practice guidelines offer consensus-based expert treatment recommendations, little is known about "real world" pharmacology decision making by practicing psychopharmacologists. MATERIALS AND METHODS: We surveyed via Internet the national membership of the American Society of Clinical Psychopharmacology (ASCP) to study preferred pharmacotherapy strategies and factors that influence medication choices for patients with mood disorders. RESULTS: Surveys were returned by 154/752 ASCP members (21%). After nonresponse to a serotonin reuptake inhibitor in major depressive disorder, participants equally favored switching within or across antidepressant classes. After a partial response, adjunctive bupropion was the preferred intervention, followed by changing antidepressant classes. Atypical antipsychotic augmentation was only a fourth-line consideration, even though moderate or marked efficacy was perceived in most instances with olanzapine, aripiprazole, and quetiapine. Respondents favored avoiding antidepressants in bipolar I patients with mixed/cycling features or prior antidepressant-associated mania/hypomania. In rapid cyclers, they advocated antidepressant cessation and preferred the use of atypical antipsychotics and lamotrigine. CONCLUSIONS: Participating psychopharmacologists treating adults with mood disorders report prescribing medications that largely mirror the evidence base with only a few notable exceptions, in consideration of the characteristics of definable clinical subpopulations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationBupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Self-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citationFava, M., Rush, A. J., Alpert, J. E., Balasubramani, G. K., Wisniewski, S. R., Carmin, C. N., Biggs, M. M., Zisook, S., Leuchter, A., Howland, R., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111868 · Cited by 927
Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., Post, R. M., Berk, M., Goodwin, G. M., Sachs, G. S., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13020185 · Cited by 770 · cited 2×
“Respondents expressed greater reluctance to use antidepressants in patients with bipolar I than bipolar II depression, those with histories of past treatment-emergent affective polarity switch, mixed states, or rapid cycling presentations, closely paralleling recent expert consensus recommendations.[25] Participants’…”
BackgroundSelf-citationMood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline
Post, R. M., Altshuler, L. L., Leverich, G. S., Frye, M. A., Nolen, W. A., Kupka, R. W., Suppes, T., McElroy, S., Keck, P. E., Denicoff, K. D., et al. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.013045 · Cited by 350 · cited 1×
“[25] Participants’ stated perceptions that bupropion or SSRIs incur less risk than TCAs or SNRIs for mood destabilization similarly reflects the current empirical literature.[26, 27] After resolution of an acute bipolar depressive episode, practice guidelines tend to advise stopping antidepressants sooner than is usua…”
BackgroundThase, M. E., Friedman, E. S., Biggs, M. M., Wisniewski, S. R., Trivedi, M. H., Luther, J. F., Fava, M., Nierenberg, A. A., McGrath, P. J., Warden, D., et al. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.5.739 · Cited by 332
Self-citationBlier, P., Ward, H. E., Tremblay, P., Laberge, L., Hébert, C., & Bergeron, R. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09020186 · Cited by 316 · cited 1×
“Those interventions are consistent with findings from randomized trials demonstrating the safety of mirtazapine added to other serotonergic antidepressants,[15] and mirtazapine’s demonstrated anxiolytic and overall efficacy in MDD with prominent anxiety symptoms.”
ResultRuhé, H. G., Huyser, J., Swinkels, J. A., & Schene, A. H. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1203 · Cited by 230
Chan, H. N., Rush, A. J., Nierenberg, A. A., Trivedi, M., Wisniewski, S. R., Balasubramani, G. K., Friedman, E. S., Gaynes, B. N., Davis, L., Morris, D., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001660 · Cited by 30
Cited by
McClintock, S. M., Reti, I. M., Carpenter, L. L., McDonald, W. M., Dubin, M., Taylor, S. F., Cook, I. A., O’Reardon, J., Husain, M. M., Wall, C., et al. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16cs10905 · Cited by 693
Mohamed, S., Johnson, G. R., Chen, P., Hicks, P. B., Davis, L. L., Yoon, J., Gleason, T. C., Vertrees, J. E., Weingart, K., Tal, I., et al. (2017) · JAMA · doi:10.1001/jama.2017.8036 · Cited by 159
“Median (IQR) 11 (7-15) 11 (7-14) 10 (7-14) CIRS Comorbidity Index”
Self-citationDe Diego-Adeliño, J., Crespo, J. M., Mora, F., Neyra, A., Iborra, P., Gutiérrez-Rojas, L., & Salonia, S. F. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2019705 · Cited by 67
Fornaro, M., Stubbs, B., De Berardis, D., Perna, G., Valchera, A., Veronese, N., Solmi, M., & Ganança, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020241 · Cited by 53
A retrospective analysis of bipolar depression treated with transcranial magnetic stimulation
Goldwaser, E. L., Daddario, K., & Aaronson, S. T. (2020) · Brain and Behavior · doi:10.1002/brb3.1805 · Cited by 15
“A problem in developing safe and effective treatment paradigms for bipolar depression is that the population is so heterogeneous and subgroups may require different pharmacologic interventions (Altshuler, Frye, & Gitlin, 2003; Goldberg et al., 2015).”
Background
Metadata
- Authors
- Goldberg, J. F., Freeman, M. P., Balon, R., Citrome, L., Thase, M. E., Kane, J. M., & Fava, M.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2015-06-30
- Volume
- 32
- Issue
- 8
- Pages
- 605-613
- ISSN
- 1091-4269 (ISSN-L)
- OpenAlex
- W1956042015
- Cited by
- 40
- References
- 10
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS’ PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS: Research Article: Mood Disorders Prescribing Survey. https://app.cochat.ai/papers/10.1002/da.22378
- The paper
- Goldberg, J. F., Freeman, M. P., Balon, R., Citrome, L., Thase, M. E., Kane, J. M., & Fava, M. (2015). THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY SURVEY OF PSYCHOPHARMACOLOGISTS’ PRACTICE PATTERNS FOR THE TREATMENT OF MOOD DISORDERS: Research Article: Mood Disorders Prescribing Survey. Depression and Anxiety. https://doi.org/10.1002/da.22378
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.